Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

GPRC5D as a novel immunotherapeutic target in multiple myeloma

Nature Reviews Clinical Oncology volume 20, pages 281–282 (2023)Cite this article

Subjects

The development of modern immune-based therapies for multiple myeloma has expanded rapidly over the past several years, and GPRC5D has been identified as a viable immunotherapeutic target. Herein, we discuss data and provide future perspectives on GPRC5D-directed CAR T cells and bispecific antibodies for patients with relapsed and/or refractory multiple myeloma.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mailankody, S. & Landgren, O. T-cell engagers — modern immune-based therapies for multiple myeloma. New Engl. J. Med. 387, 558–561 (2022).

    Article  PubMed  Google Scholar 

  2. Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11, eaau7746 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pillarisetti, K. et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 135, 1232–1243 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. New Engl. J. Med. 387, 1196–1206 (2022).

    Article  CAS  PubMed  Google Scholar 

  5. Bal, S. et al. Clinical activity of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and/or refractory (R/R) multiple myeloma (MM): first results from a phase 1, multicenter, open-label study. Blood 140, 883–885 (2022).

    Article  Google Scholar 

  6. Huang, H. et al. Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS). J. Clin. Oncol. 40, 8004–8004 (2022).

    Article  Google Scholar 

  7. Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. New Engl. J. Med. 387, 2232–2244 (2022).

    Article  CAS  PubMed  Google Scholar 

  8. Carlo-Stella, C. et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood 140, 397–399 (2022).

    Article  Google Scholar 

  9. Falchi, L., Vardhana, S. A. & Salles, G. A. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns and opportunities. Blood https://doi.org/10.1182/blood.2021011994 (2022).

    Article  Google Scholar 

  10. Fernández de Larrea, C. et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 1, 146–154 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

K.N. and S.M. gratefully acknowledge the US National Cancer Institute Cancer Centre Support Grant (P30 CA008748) to Memorial Sloan Kettering Cancer Centre.

Author information

Authors and Affiliations

  1. Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Karthik Nath & Sham Mailankody

  2. Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Bruno A. Costa

  3. Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer, New York, NY, USA

    Sham Mailankody

  4. Department of Medicine, Weill Cornell Medicine, New York, NY, USA

    Sham Mailankody

Authors
  1. Karthik Nath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno A. Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sham Mailankody
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sham Mailankody.

Ethics declarations

Competing interests

S.M. has acted as a consultant of Evicore, Janssen, Legend Biotech and Optum Oncology, receives honoraria from MJH Life sciences, Physician Education Resource and Plexus Education, and acknowledges research funding from Allogene Therapeutics Bristol Myers Squibb, Fate Therapeutics, Janssen Oncology, Juno Therapeutics and Takeda Oncology. K.N. and B.A.C. declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nath, K., Costa, B.A. & Mailankody, S. GPRC5D as a novel immunotherapeutic target in multiple myeloma. Nat Rev Clin Oncol 20, 281–282 (2023). https://doi.org/10.1038/s41571-023-00735-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-023-00735-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing